ClearNote Health will present new multi-cohort validation data for its Avantect Pancreatic Cancer Test at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, where the diagnostics-focused company will showcase performance results in people at elevated risk of pancreatic cancer. The data cover an independent validation cohort of 1,445 individuals with multiple risk factors and two additional validation cohorts totaling 338 individuals enriched for new-onset type 2 diabetes, positioning Avantect as a blood-based test aimed at earlier pancreatic cancer detection in clinically defined high-risk populations.
Why ClearNote Health’s Avantect data matters for early pancreatic cancer detection
The significance of ClearNote Health’s ASCO 2026 presentation lies less in the existence of another liquid biopsy test and more in the population it is trying to address. Pancreatic cancer remains one of oncology’s most difficult early detection problems because many patients are diagnosed only after the disease has progressed beyond the window where curative intervention is more feasible. For diagnostics developers, the central challenge is not simply identifying cancer-associated signals in blood, but doing so with enough accuracy in a population where false positives, missed early disease, downstream imaging, patient anxiety, and reimbursement scrutiny all matter.
Avantect is being positioned for people with elevated pancreatic cancer risk rather than for broad population screening. That distinction matters. A blood test used in an average-risk population would face a much steeper bar because pancreatic cancer is relatively uncommon, which can make even highly specific tests difficult to deploy without generating unnecessary follow-up procedures. By focusing on individuals with genetic predisposition, family history, or new-onset type 2 diabetes after age 50, ClearNote Health is targeting a narrower clinical use case where the probability of disease is higher and the case for surveillance may be easier to defend.
The reported performance figures are strong enough to attract attention. In the 1,445-person independent validation cohort, Avantect showed 82.6% overall sensitivity, 76.8% sensitivity for Stage I and Stage II disease, and 97.5% specificity. For a pancreatic cancer early detection test, early-stage sensitivity is especially important because the commercial and clinical promise rests on identifying cancer before symptoms or advanced disease dominate the diagnosis pathway. However, validation data presented at a scientific meeting are still not the same as proof of broad clinical utility. The next question is whether improved detection can translate into changes in care pathways, earlier intervention, improved survival outcomes, and payer confidence.
What the multi-analyte design reveals about the direction of liquid biopsy development
ClearNote Health’s test reflects a broader shift in cancer diagnostics away from single-signal detection models and toward multi-analyte platforms that combine different biological inputs. Avantect integrates epigenomic, fragmentomic, genotyping, and glycan-specific signals into a multimodal cancer detection model. That approach is aligned with where the liquid biopsy field has been heading, particularly for cancers that are hard to detect early because they may shed limited tumor material into the bloodstream.
The value of a multi-analyte model is that different biological signals may capture different aspects of cancer biology. Epigenomic patterns can provide insight into cancer-associated regulatory changes. Fragmentomic signals can reflect patterns in circulating DNA structure. Genotyping can add mutation-related information, while glycan-specific measures may contribute another layer of cancer-associated biology. In theory, combining these signal classes can improve detection performance compared with approaches that rely on one biological marker.
The risk, however, is complexity. Multi-analyte tests can be harder to explain to clinicians, payers, and regulators than simpler assays with a single well-understood biomarker. The more complex the model, the more important it becomes to show that performance is reproducible across different clinical settings, sample types, patient demographics, and disease-adjacent conditions. For pancreatic cancer detection, where inflammatory disease, diabetes, aging, and gastrointestinal symptoms can complicate clinical interpretation, robustness across real-world populations will matter as much as headline sensitivity and specificity.
Why the elevated-risk population could shape Avantect’s adoption pathway
ClearNote Health’s focus on elevated-risk individuals gives Avantect a clearer clinical entry point. The test is intended for patients with known genetic predispositions, family history of pancreatic cancer, or those aged 50 and older who have been newly diagnosed with type 2 diabetes. These groups are already central to many discussions about pancreatic cancer surveillance because they may carry higher disease risk than the general population.
New-onset type 2 diabetes is particularly important because it has long been studied as a potential clinical signal associated with pancreatic cancer risk in older adults. The inclusion of additional validation cohorts enriched for new-onset type 2 diabetes suggests ClearNote Health is trying to build evidence around a population that could be large enough to support commercial scale but clinically specific enough to justify testing. That is a delicate balance. A population that is too narrow may limit adoption, while a population that is too broad may create pressure around false positives and cost-effectiveness.
The involvement of the SAFE-D study led by the NHS in the United Kingdom could be important for credibility because large structured studies can help determine how a test performs when embedded in a real surveillance workflow. Similarly, incorporation into the PRECEDE Consortium gives Avantect exposure to international high-risk pancreatic cancer research networks. These external study settings do not eliminate risk, but they may help generate the kind of prospective, clinically contextualized evidence that diagnostics companies often need before broader adoption becomes realistic.
How the ASCO validation data could influence clinician and payer confidence
The reported specificity of 97.5% is likely to be closely watched because specificity is central to the practical adoption of early detection tests. A false positive in pancreatic cancer screening is not a trivial issue. It may lead to advanced imaging, specialist referral, invasive procedures, cost escalation, and psychological burden. Clinicians will want to know not only how many cancers the test can detect, but also how many patients without cancer may be pushed into follow-up pathways.
The 76.8% early-stage sensitivity figure is also notable because Stage I and Stage II disease is where early detection has the greatest theoretical value. However, industry observers are likely to focus on how the early-stage cases were distributed, how many Stage I cases were included, and whether performance holds up across subgroups. A test that performs well in a validation cohort may still face questions if the number of early-stage cancers is limited or if performance varies by risk factor category.
Payers will likely ask a different but related set of questions. They will want evidence that using the test changes clinical management in a meaningful way. That could include whether Avantect leads to earlier imaging, more timely diagnosis, improved surgical eligibility, better survival outcomes, or reduced downstream costs. In diagnostics, analytical and clinical validation are necessary, but they are often not sufficient for broad reimbursement. The commercial hurdle is proving that the test is not only accurate, but useful within a defined care pathway.
What remains unresolved for ClearNote Health’s pancreatic cancer test strategy
ClearNote Health’s ASCO 2026 data could strengthen the company’s position in blood-based early cancer detection, but several unresolved questions remain. The most important is clinical utility. Sensitivity and specificity are powerful validation metrics, but clinicians need to understand what happens after a positive Avantect result. A test designed for high-risk populations must fit into a clear follow-up pathway involving imaging, specialist assessment, repeat testing, or surveillance escalation.
Another key question is whether Avantect can be adopted consistently across health systems. Pancreatic cancer surveillance is not as standardized as screening for diseases such as breast, colorectal, or cervical cancer. High-risk programs often vary by institution, genetic risk category, local expertise, access to imaging, and specialist availability. A blood test could make surveillance more accessible, but only if clinicians have confidence in how to act on results.
There is also the issue of reimbursement and health economics. Early detection tests for lethal cancers can appear compelling clinically, but payer adoption depends on evidence quality, patient selection, cost per diagnosis, downstream procedure burden, and long-term outcomes. If Avantect is used in tightly defined high-risk populations, the reimbursement argument may be more manageable. If ClearNote Health eventually seeks broader use, the evidence burden will rise sharply.
Why ASCO visibility could support ClearNote Health’s broader diagnostics ambitions
ASCO provides a high-profile setting for ClearNote Health because oncology diagnostics companies increasingly need to speak to multiple audiences at once. Clinicians want evidence that the test can help guide care. Regulators and laboratory oversight bodies want confidence in performance and quality systems. Payers want proof of value. Investors and strategic partners want to see whether the technology platform can expand beyond one indication.
ClearNote Health’s broader platform story is also relevant. The diagnostics-focused company says its Virtuoso epigenomics platform was developed from work in the Stephen Quake laboratory at Stanford University and uses artificial intelligence and bioinformatics to measure biological differences between cancer and healthy cells in blood. Avantect pancreatic and ovarian tests represent disease-specific applications of that platform, while the company’s multi-cancer detection test has also been selected for the National Cancer Institute’s Vanguard Study.
That broader platform context matters because liquid biopsy companies are rarely valued only on one test. Their long-term positioning often depends on whether the underlying technology can support multiple indications, multiple risk populations, and evidence generation at scale. For ClearNote Health, the pancreatic cancer data may serve as both a clinical proof point and a commercial credibility test. The opportunity is meaningful, but so is the challenge of moving from promising validation results to routine clinical adoption.
What clinicians and industry observers will watch after the ASCO 2026 presentation
The next phase for ClearNote Health will depend on how the Avantect data are interpreted by oncology, gastroenterology, endocrinology, genetics, and diagnostics stakeholders. Clinicians will likely examine the validation design, cohort composition, disease-stage distribution, subgroup performance, and real-world relevance. They will also want clarity on how the test should be used alongside imaging, genetic testing, family-history assessment, and diabetes-linked risk evaluation.
Industry observers will also watch whether Avantect can build momentum through ongoing studies such as SAFE-D and PRECEDE. Those programs could help answer a critical question: can a blood-based test identify pancreatic cancer early enough in high-risk individuals to change outcomes? That is the question that separates a technically impressive diagnostic from a clinically transformative one.
For now, ClearNote Health’s ASCO 2026 presentation gives Avantect a stronger place in the pancreatic cancer early detection conversation. The performance figures suggest a potentially meaningful advance in high-risk testing, especially if replicated in prospective settings. The real test, however, will be whether clinicians, payers, and health systems view Avantect not just as another liquid biopsy assay, but as a practical tool that can fit into the difficult and still-evolving pathway for pancreatic cancer surveillance.
ClearNote Health targets early pancreatic cancer detection with multi-analyte blood test data added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →